Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-12-08 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the rules, responsibilities, qualifications, and procedures related to independent directors of the company. It references relevant laws, regulations, and company bylaws. The content is a governance framework document rather than a financial report, announcement, or meeting material. It does not contain financial data, voting results, or executive changes. It is a governance-related policy document outlining internal rules and practices for independent directors. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7531 characters) supports it being a full policy document rather than a brief announcement or report publication notice.
2023-12-08 Chinese
第四届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting, including details about meeting attendance, agenda items, and voting results. It discusses changes to the company's articles of association, governance rules, and plans to convene a shareholders meeting. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full report but an announcement of board decisions and upcoming shareholder meeting proposals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2023-12-08 Chinese
关于召开2023年第四次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 fourth extraordinary general meeting (临时股东大会) of the company 拓新药业集团股份有限公司. It includes information about the meeting date, voting procedures (both onsite and online), agenda items for shareholder approval, registration details, and proxy voting instructions. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and invitation to shareholders to participate in the meeting and vote on specific proposals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length (5161 characters) and content confirm it is not a brief announcement or a report publication notice but a full meeting notice with voting instructions and agenda details.
2023-12-08 Chinese
关联交易决策制度
Governance Information Classification · 95% confidence The document is titled '拓新药业集团股份有限公司 关联交易决策制度' which translates to 'Related Party Transaction Decision System' of the company. It is a detailed internal policy document outlining the principles, definitions, procedures, and responsibilities related to related party transactions. It includes references to relevant laws, company bylaws, and regulatory requirements, but it is not a financial report, earnings release, or announcement. It is a governance-related document describing internal rules and procedures for managing related party transactions. Therefore, it fits best under Governance Information (CGR). The document length is over 6000 characters, indicating it is a full policy document rather than a brief announcement or notice.
2023-12-08 Chinese
拓新药业集团股份有限公司章程
Governance Information Classification · 95% confidence The document is a detailed corporate charter or articles of association for Tuoxin Pharmaceutical Group Co., Ltd., covering company governance, shareholder rights, board structure, share issuance, and meeting procedures. It includes chapters on general provisions, business scope, shares, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting, profit distribution, audit, notices and announcements, mergers, disputes, amendments, and appendices. The content is legal and governance-related, focusing on internal rules and organizational structure rather than financial results, audit opinions, or meeting announcements. It does not contain financial statements or earnings data, nor is it a meeting presentation or voting result announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-08 Chinese
独立董事专门会议议事规则
Governance Information Classification · 95% confidence The document is titled as '独立董事专门会议议事规则' which translates to 'Rules of Procedure for Independent Directors' Special Meetings' of the company. It details the governance rules, meeting procedures, voting rights, and responsibilities of independent directors. There is no financial data, no report of financial results, no announcement of voting results, no management changes, no legal proceedings, no capital updates, and no earnings information. The document is a governance-related internal rules document describing board structure and governance practices. Therefore, it fits the category of Governance Information (CGR). The document length is 2687 characters, which is consistent with a detailed governance document rather than a brief announcement or report publication notice.
2023-12-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.